- BASF
- Bill and Melinda Gates Foundation
- Canada
- Carter Center
- Clark Foundation
- Denmark
- DuPont
- FAO
- GAVI
- Helen Keller International
- Inter-American Development Bank
- Intenational Trachoma Initiative
- Japan
- Merck & Co., Inc
- Norway
- PAHO
- Pfizer Inc.
- Precision Fabrics
- Rotary International
- Sanofi-Pasteur
- Sweden
- The Netherlands
- UNDP
- UNICEF
- United Kingdom
- United States
- US Centers for Disease Control and Prevention
- WHO
- World Bank
In 1987, Merck pledged to donate indefinitely their antiobiotic Mectizan to the fight against onchocerciasis in Africa. The Merck Mectizan Donation Program was established to distribute the drug, creating one of the largest ever public-private partnerships. Since 1988, Merck has donated more than 300 million treatments. The donation has fueled the success of both the Onchocerciasis Control Program – which has halted transmission in 11 west African countries and prevented 600,000 cases of blindness – and the African Programme for Onchocerciasis Control, which aims to eliminate river blindness in central and east Africa. Merck has reconfirmed its commitment to indefinite donation of the drug, and in 1998 broadened its mandate to include the donation of Mectizan for the treatment of lymphatic filariasis in co-endemic areas.